Selective ATM inhibition augments radiation-induced inflammatory signaling and cancer cell death

Li-Ya Chiu1, Qing Sun1, Frank T Zenke2

  • 1Translational Innovation Platform Oncology and Immuno-Oncology, EMD Serono, Billerica, MA 01821, USA.

Aging
|January 19, 2023
PubMed

Insights

New ATM inhibitors enhance radiation therapy by causing cancer cell death through mitotic abnormalities and immune signaling. This combination strategy shows promise for radio-immunotherapy of advanced tumors.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Radiation therapy is a common cancer treatment, but combination strategies with targeted drugs are needed for better efficacy.
  • Targeting DNA damage response pathways, like ATM kinase, is a promising approach for radiosensitization.

Purpose of the Study:

  • To investigate the cellular mechanisms by which ATM inhibitors (M3541, M4076) enhance cancer cell killing by radiation.
  • To explore the potential of combining ATM inhibitors with other immunotherapies, such as PD-L1 blockade.

Main Methods:

  • Treatment of cancer cells with ATM inhibitors (M3541, M4076) and radiation.
  • Analysis of cell cycle progression, DNA damage, and cell death.
  • Assessment of immune signaling pathways (cGAS/STING/TBK1) and NK cell cytotoxicity.
  • Evaluation of PD-L1 expression in surviving cells.

Main Results:

  • ATM inhibition abrogated radiation-induced G1 checkpoint activation, leading to enhanced cell death.
  • Mitotic catastrophe, characterized by chromosomal abnormalities and micronuclei formation, was the primary mechanism of cell killing.
  • Radiation with M3541 treatment activated the cGAS/STING/TBK1 interferon response and increased susceptibility to NK cell killing.
  • Upregulation of PD-L1 was observed in surviving cells, suggesting potential for immunotherapy combinations.

Conclusions:

  • ATM inhibitors M3541 and M4076 effectively radiosensitize cancer cells by inducing mitotic catastrophe and immune activation.
  • The combination of radiation, ATM inhibitors, and PD-L1 blockade represents a novel radio-immunotherapy strategy for locally advanced tumors.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
DNA Damage can Stall the Cell Cycle02:37

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
9.2K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K